Polymyositis Market

Market Overview:

The 7 major polymyositis markets are expected to exhibit a CAGR of 3.52% during 2024-2034.

The polymyositis market has been comprehensively analyzed in IMARC's new report titled "Polymyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polymyositis is a rare autoimmune disease characterized by chronic inflammation and progressive weakening of the skeletal muscles. This condition primarily affects the muscles closest to the trunk of the body, such as those in the hips, thighs, shoulders, and neck. The symptoms of the ailment typically include muscle weakness, muscle pain, and fatigue. Individuals suffering from this illness may also experience difficulty climbing stairs, lifting objects, or even getting up from a seated position. As the condition advances, it can result in muscle atrophy and impair one's ability to perform everyday tasks. The diagnosis of polymyositis involves a combination of clinical evaluation, blood tests, electromyography (EMG), and a muscle biopsy. Elevated concentrations of muscle enzymes, such as creatine kinase (CK), in the blood often indicate muscle damage. Furthermore, EMG helps to assess muscle function, while a muscle biopsy provides definitive evidence of inflammation and muscle fiber damage.

The escalating cases of rare autoimmune diseases, which mainly affect the skeletal muscles and cause abnormalities in the production of autoantibodies, are primarily driving the polymyositis market. In addition to this, the inflating utilization of potent medications, such as corticosteroids, immunosuppressants, and intravenous immunoglobulins, to manage the symptoms and mitigate the immune system's response against the muscles is also creating a positive outlook for the market. These therapies play a crucial role in reducing inflammation and enhancing muscle function, thereby improving the quality of life for individuals suffering from the ailment. Moreover, the widespread adoption of physical and occupational therapies on account of their several benefits, like restoring muscle strength, stabilizing mobility, and boosting overall physical activity, is further bolstering the market growth. Apart from this, the rising usage of novel therapeutic approaches, such as biologics and targeted therapies, which can address the underlying immune system dysfunction and decrease the frequency of disease relapses, thereby offering more effective and targeted solutions for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapies aimed at rectifying genetic anomalies and regulating aberrant immune responses responsible for the disorder is expected to drive the polymyositis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the polymyositis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polymyositis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polymyositis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the polymyositis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the polymyositis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current polymyositis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the polymyositis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the polymyositis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the polymyositis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of polymyositis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of polymyositis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of polymyositis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with polymyositis across the seven major markets?
• What is the size of the polymyositis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of polymyositis?
• What will be the growth rate of patients across the seven major markets?
   

Polymyositis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for polymyositis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polymyositis market?
• What are the key regulatory events related to the polymyositis market?
• What is the structure of clinical trial landscape by status related to the polymyositis market?
• What is the structure of clinical trial landscape by phase related to the polymyositis market?
• What is the structure of clinical trial landscape by route of administration related to the polymyositis market?